Company

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
BayerETR: BAYN

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian 50 mg tablets, under the brand name Sunharbo — the first…

Charles River to Acquire Frontage's Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Merck's Keytruda Gains NMPA Approval for HNSCC Indication in China
MerckMerck Sharp & Dohme

Merck’s Keytruda Gains NMPA Approval for HNSCC Indication in China

Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors
Clinical trial approval / initiationHuadong Medicine

Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors

Zhaoke Ophthalmology Partners with AFT for Brimochol PF Distribution in ANZ
AFT PharmaceuticalsHKG: 6622

Zhaoke Ophthalmology Partners with AFT for Brimochol PF Distribution in ANZ

Tonghua Dongbao Begins Phase II Trial for GLP-1/GIP Agonist THDBH120 in Weight Loss
Clinical trial approval / initiationObesity

Tonghua Dongbao Begins Phase II Trial for GLP-1/GIP Agonist THDBH120 in Weight Loss

Show More